CA
NZ
UK
AU
IND
US
Investors are balancing a mixed analyst outlook ahead of a pivotal FDA advisory committee meeting on peptides scheduled for July 23-24. BofA recently raised its price target to $37 while Canaccord sits at $40, but Truist maintained a Hold with a $23 target citing …
Raymond James raised its price target on Delek from $60 to $70 while maintaining an Outperform rating, a significant analyst catalyst for the stock. U.S.-Iran tensions are pushing crude oil prices sharply higher, with energy emerging as a leading sector for Q2 earnings growth.
The decline follows completion of the sale of sevasemten and the company's muscular dystrophy business to Servier for $1.55 billion upfront, up to $2.65 billion total, as Edgewise pivots fully to cardiovascular drugs. The pullback appears driven by profit-taking following a roughly 23.5% five-day …
A broader pullback in basic materials weighs on shares, with the XLB sector ETF also trading lower and the materials sector posting its worst weekly performance last week, down 2.46%. Trump's renewed Greenland ambitions at the NATO summit in Ankara last week briefly lifted …
The healthcare sector is under pressure heading into Q2 earnings season, with the XLV ETF trading modestly lower and a reported 9% Q2 earnings decline for the sector, largely driven by accounting quirks at Gilead. Despite near-term headwinds, analyst sentiment on Definium remains constructive: …
Renewed U.S.-Iran hostilities have rattled risk appetite broadly, pressuring high-beta AI infrastructure names, while persistent concerns about heavy insider selling continue to cloud the investment case. Executives have offloaded over 26 million shares worth approximately $3 billion in the past quarter, and competition pressures …
Shares are caught in a broad semiconductor selloff as renewed U.S.-Iran hostilities rattle global markets and pressure the chip sector ahead of a critical earnings week. The decline comes despite a strong fundamental backdrop, with Q4 fiscal 2026 revenue surging 157% year-over-year to $437 …
The stock is giving back a significant portion of last week's gains, which were driven by the landmark OCC approval to establish First National Digital Currency Bank (Circle National Trust), making Circle the first stablecoin issuer with a federal banking charter. Renewed U.S.-Iran hostilities …
The stock is extending a steep multi-week selloff that has now erased roughly 33% from its recent highs, as dual short-seller reports from Hunterbrook Capital and Crossroads Capital continue to weigh on sentiment. The reports allege that Bloom relies heavily on Chinese-sourced scandium, a …
CBIZ reported Q1 2026 EPS of $2.50, surpassing estimates by over 12%, while a recent shift in Russell value/growth index classifications has attracted fresh buying interest. Gains build on ongoing investor enthusiasm around the successful integration of the Marcum acquisition, which drove a 52% …
Please wait processing your request...